Heinrichs S, Kulkarni R V, Bueso-Ramos C E, Levine R L, Loh M L, Li C, Neuberg D, Kornblau S M, Issa J-P, Gilliland D G, Garcia-Manero G, Kantarjian H M, Estey E H, Look A T
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Leukemia. 2009 Sep;23(9):1605-13. doi: 10.1038/leu.2009.82. Epub 2009 Apr 23.
Progress in the management of patients with myelodysplastic syndromes (MDS) has been hampered by the inability to detect cytogenetic abnormalities in 40-60% of cases. We prospectively analyzed matched pairs of bone marrow and buccal cell (normal) DNA samples from 51 MDS patients by single nucleotide polymorphism (SNP) arrays, and identified somatically acquired clonal genomic abnormalities in 21 patients (41%). Among the 33 patients with normal bone marrow cell karyotypes, 5 (15%) had clonal, somatically acquired aberrations by SNP array analysis, including 4 with segmental uniparental disomies (UPD) and 1 with three separate microdeletions. Each abnormality was detected more readily in CD34+ cells than in unselected bone marrow cells. Paired analysis of bone marrow and buccal cell DNA from each patient was necessary to distinguish true clonal genomic abnormalities from inherited copy number variations and regions with apparent loss of heterozygosity. UPDs affecting chromosome 7q were identified in two patients who had a rapidly deteriorating clinical course despite a low-risk International Prognostic Scoring System score. Further studies of larger numbers of patients will be needed to determine whether 7q UPD detected by SNP array analysis will identify higher risk MDS patients at diagnosis, analogous to those with 7q cytogenetic abnormalities.
骨髓增生异常综合征(MDS)患者的治疗进展一直受到阻碍,因为在40%-60%的病例中无法检测到细胞遗传学异常。我们通过单核苷酸多态性(SNP)阵列对51例MDS患者的骨髓和颊细胞(正常)DNA样本进行了配对前瞻性分析,在21例患者(41%)中鉴定出体细胞获得性克隆基因组异常。在33例骨髓细胞染色体核型正常的患者中,5例(15%)通过SNP阵列分析存在克隆性体细胞获得性畸变,包括4例节段性单亲二体(UPD)和1例有三个独立微缺失的患者。每种异常在CD34+细胞中比在未选择的骨髓细胞中更容易检测到。对每位患者的骨髓和颊细胞DNA进行配对分析,对于区分真正的克隆基因组异常与遗传拷贝数变异以及明显杂合性缺失区域是必要的。在两名患者中鉴定出影响7号染色体长臂的UPD,尽管国际预后评分系统评分为低危,但他们的临床病程迅速恶化。需要对更多患者进行进一步研究,以确定通过SNP阵列分析检测到的7号染色体长臂UPD是否能在诊断时识别出高危MDS患者,类似于那些有7号染色体长臂细胞遗传学异常的患者。